ArticlePreventive medicine reports2026
Persistent glycemic deterioration after the COVID-19 pandemic: A large cohort analysis stratifying by care settings, specialties, and gender disparities in Chengdu, China.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to quantify the sustained impact of the Coronavirus Disease 2019(COVID-19) pandemic on glycemic control across distinct healthcare settings, medical specialties, and demographic groups. Methods: We conducted a retrospective analysis of 274,909 glycated hemoglobin(HbA1c) records from a tertiary hospital in Chengdu,China between 2013 and 2025. Non-parametric tests were used to compare median HbA1c levels across pre-pandemic, pandemic, peak-infection, and post-pandemic phases, stratified by Healthcare Settings, specialty, age, and gender. Results: Significant deterioration in glycemic control was observed during the pandemic period and sustained thereafter. Median HbA1c increased from 5.9 % (pre-pandemic) to 6.4 % (peak infection), remaining elevated at 6.2 % post-pandemic ( Conclusion: The COVID-19 pandemic resulted in persistent glycemic deterioration, particularly affecting outpatient management, acute care settings, and vulnerable demographic groups. These findings highlight critical gaps in diabetes care resilience and underscore the need for targeted interventions in high-risk settings and strengthened support systems for susceptible populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.